Business & regional news

Month Year

Email alerts

Sep 28, 2022

Medtronic Nexpowder™* Endoscopic Hemostasis System Receives U.S. FDA Clearance

-- Nexpowder™* provides gastroenterologists improved visibility, controls upper gastrointestinal (GI) bleeding effectively and with ease^1,2,3 --

-- Nexpowder™* endoscopic hemostasis system showed a lower rebleeding rate and has nearly double the adhesive force of other hemostatic sprays^2,3 --
- Gastrointestinal
Sep 21, 2022

Medtronic Ranked One of 2022 Best Workplaces in Asia™

Medtronic been ranked fifth in the 2022 Best Workplaces in Asia list by Great Place to Work, the global authority on workplace culture. This is a significant improvement of six places from 2021....
- Asia Pacific
Sep 21, 2022

Medtronic is the first and only company to receive FDA indication for bifurcation percutaneous coronary intervention with a drug-eluting stent

Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...
- Coronary and Renal Denervation
Sep 20, 2022

Medtronic receives CE mark for the first balloon expandable covered stent indicated for chimney endovascular aneurysm repair (ChEVAR)

Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...
- Structural Heart and Aortic
Sep 18, 2022

MEDTRONIC UNVEILS NEW DATA FROM INVESTIGATIONAL INTREPID™ TRANSCATHETER MITRAL VALVE REPLACEMENT PROGRAM TO EXPAND TREATMENT OPTIONS FOR SEVERE MITRAL REGURGITATION

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...
- Structural Heart and Aortic

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa